Tag:
Christoph Westphal
Latest Headlines
Latest Headlines
Company 'insiders' left with 43% of Verastem's shares
Anyone trying to understand what it takes to pull off a successful biotech IPO these days should check out a series of 13Ds Verastem's ( $VSTM ) insiders filed last month. In the days after...
Westphal pulls off a rare stunt with $55M Verastem IPO
Christoph Westphal's Verastem, a preclinical-stage biotech focused on cancer stem cell research, seemingly defied gravity with an announcement late last night that its IPO raised $55 million from the
Fledgling Verastem outlines investor strategy behind high-risk $50M IPO
As today's report on 2011's small class of biotech IPOs makes clear, this is a lousy time for a drug developer to go public--even if it has a compelling late-stage program to boast about. But
Verastem papers $20M C round amid IPO pursuit
Verastem won't go hungry during its unlikely hunt for an initial public offering. The Cambridge, MA-based biotech, which is researching drugs that target cancer stem cells, has filed paperwork for a
Upstart Verastem challenges Wall Street with puzzling $50M IPO
Just a few months ago Christoph Westphal's new biotech, Verastem, raised a hefty $32 million Series B round based on the promise of the developer's cancer stem cell technology and a trio of noted
GSK's VC unit SR One has new chief
There's some new blood at the helm of London-based drug giant GlaxoSmithKline's venture group. Jens Eckstein, previously a venture partner and entrepreneur-in-residence at TVM Capital, has jumped
Westphal leaving SR One, concentrating on VC firm
After only a short run at the helm of SR One, GlaxoSmithKline's ambitious venture arm, Dr. Christoph Westphal is on his way out. The co-founder of Sirtris, who helped engineer the sale of the biotech
Westphal VC group backs a cancer stem cell startup
Christoph Westphal's new venture fund, the Longwood Founders Fund, has found a home for some of its investment cash. Longwood joined Bessemer Venture Partners, Cardinal Partners, and MPM Capital in a
Westphal offers optimistic outlook for regenerative medicine
Christoph Westphal is one of the biotech industry's most prominent optimists. And he showed just how bullish he could be about the potential for groundbreaking drug discovery in a new column he
Westphal grabs reins at GSK's SR One, founds new venture group
Christoph Westphal is adding a new chapter to his story as a prime mover-and-shaker in biotech circles. Xconomy reports that Westphal has resigned as CEO of Sirtris, a high-profile developer in
